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The Delta:Notch signaling pathway regulates numerous
aspects of differentiation, morphogenesis and cell func-
tion, during embryogenesis and throughout adult life.
More recently, Delta-like 4 (Dll4) has been shown to
regulate adult neo-vascularization (angiogenesis). Conse-
quently, therapeutic strategies to target Dll4 have been
put forward for the treatment of different cancers. In
the present study, we describe for the first time that
Dll4 blockade affects the bone marrow (BM) microen-
vironment, by perturbing the BM vascular niche. Anti-
Dll4 treatment administered 1 day after myeloablation
increased the BM vascular content (CD31
+ cells), pro-
moted megakaryopoiesis and promoted hematopoietic
(Sca1
+) and endothelial progenitor (Flk1
+CXCR4
+) cell
mobilization to the peripheral blood (PB). Moreover,
anti-Dll4 treatment increased BM myeloid content, and





-) lymphocytes to the PB. Taken together,
we show that Dll4 blockade affects the BM vascular
niche, and as such affects hematopoietic cell differentia-
tion and mobilization.
Author details
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE,
Lisbon, Portugal.
2CEDOC, FCM, Universidade Nova de Lisboa, Lisbon,
Portugal.
3Instituto Gulbenkian de Ciência, Oeiras, Portugal.
Published: 24 September 2010
doi:
Cite this article as: Remédio et al.: Dll4 blockade interferes with the
bone marrow vascular niche and perturbs hematopoietic recovery
following myeloablation. BMC Proceedings 2010 4(Suppl 2):P38.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: leonor.remedio@gmail.com
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE,
Lisbon, Portugal
Full list of author information is available at the end of the article
Remédio et al. BMC Proceedings 2010, 4(Suppl 2):P38
http://www.biomedcentral.com/1753-6561/4/S2/P338
© 2010 Remédio et al; licensee BioMed Central Ltd.